Novartis AG Share Price Today: Live Updates & Key Insights

Novartis AG share price today is $146.09, up -1.46%. The stock opened at $148.77 against the previous close of $148.19, with an intraday high of $148.9 and low of $145.3.

Novartis AG Share Price Chart

Novartis AG

us-stock
To Invest in {{usstockname}}
us-stock

Novartis AG Share Price Performance

$146.09 -0.0146(-1.46%) NVS at 23 Mar 2026 02:32 PM Drug Manufacturers - General
Lowest Today 145.3
Highest Today 148.9
Today’s Open 148.77
Prev. Close 148.19
52 Week High 165.43
52 Week Low 94.83
Day’s Range: Low 145.3 High 148.9
52-Week Range: Low 94.83 High 165.43
1 day return -
1 Week return -5.7
1 month return -11.35
3 month return +6.65
6 month return +18.33
1 year return +31.36
3 year return +88.21
5 year return +78.44
10 year return -

Novartis AG Institutional Holdings

Dodge & Cox 0.47

Dimensional Fund Advisors, Inc. 0.45

Morgan Stanley - Brokerage Accounts 0.41

PRIMECAP Management Company 0.40

Fisher Asset Management, LLC 0.39

Dodge & Cox Stock I 0.36

Loomis, Sayles & Company LP 0.29

Vanguard PRIMECAP Inv 0.27

Bank of America Corp 0.24

Franklin Resources Inc 0.21

GQG Partners LLC 0.17

The Goldman Sachs Group Inc 0.15

BlackRock Inc 0.13

Northern Trust Corp 0.12

DFA International Core Equity 2 I 0.11

Principal Financial Group Inc 0.11

Cullen Capital Management, LLC 0.11

HHG PLC 0.11

Wells Fargo & Co 0.10

QRG Capital Management, Inc. 0.10

Russell Investments Core Equity SMA 0.09

Franklin Mutual Global Discovery Z 0.09

FMR Inc 0.09

UBS Group AG 0.08

Loomis Sayles Growth Y 0.08

State Street Corp 0.08

Vanguard Capital Opportunity Inv 0.06

Franklin Mutual Shares Z 0.06

Principal Equity Income A 0.05

Janus Henderson Global Life Sciences 0.05

Janus Henderson Global Life Sciences D 0.05

Dimensional International Value ETF 0.05

VanEck Pharmaceutical ETF 0.05

Janus Henderson Glb Life Scn I2 USD 0.05

Janus Global Life Science AUSD 0.04

Franklin Mutual Beacon Z 0.04

GQG Partners US Select Quality Eq Instl 0.04

Dimensional International Core Eq 2 ETF 0.04

Vanguard PRIMECAP Core Inv 0.04

Dimensional International Cr Eq Mkt ETF 0.04

Novartis AG Market Status

Strong Buy: 0

Buy: 2

Hold: 9

Sell: 0

Strong Sell: 2

Novartis AG Fundamentals

Market Cap 282286.26 M

PB Ratio 6.0405

PE Ratio 20.3953

Enterprise Value 302072.55 M

Total Assets 115569.20 M

Volume 2019872

Novartis AG Company Financials

Annual Revenue FY25:54811252000 54811.3M, FY24:51722000000 51722.0M, FY23:54217000000 54217.0M, FY22:51828000000 51828.0M, FY21:52877000000 52877.0M

Annual Profit FY25:41121506000 41121.5M, FY24:38895000000 38895.0M, FY23:37822000000 37822.0M, FY22:36342000000 36342.0M, FY21:37010000000 37010.0M

Annual Net worth FY25:14055610000 14055.6M, FY24:11941000000 11941.0M, FY23:7836000000 7836.0M, FY22:6955000000 6955.0M, FY21:24021000000 24021.0M

Quarterly Revenue Q4/2025:13334986000 13335.0M, Q3/2025:14358000000 14358.0M, Q2/2025:14836000000 14836.0M, Q1/2025:13620000000 13620.0M, Q4/2024:13558000000 13558.0M

Quarterly Profit Q4/2025:9793255000 9793.3M, Q3/2025:10819000000 10819.0M, Q2/2025:11514000000 11514.0M, Q1/2025:10393000000 10393.0M, Q4/2024:10234000000 10234.0M

Quarterly Net worth Q4/2025:2408817000 2408.8M, Q3/2025:3928000000 3928.0M, Q2/2025:4041000000 4041.0M, Q1/2025:3606000000 3606.0M, Q4/2024:2818000000 2818.0M

About Novartis AG & investment objective

Company Information Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Organisation Drug Manufacturers - General

Employees 75267

Industry Drug Manufacturers - General

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Novartis AG FAQs

What is the share price of Novartis AG today?

The current share price of Novartis AG is $146.09.

Can I buy Novartis AG shares in India?

Yes, Indian investors can buy Novartis AG shares by opening an international trading and demat account with Motilal Oswal.

How to buy Novartis AG shares in India?

You can easily invest in Novartis AG shares from India by:

Can I buy fractional shares of Novartis AG?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Novartis AG?

Novartis AG has a market cap of $282286.26 M.

In which sector does Novartis AG belong?

Novartis AG operates in the Drug Manufacturers - General sector.

What documents are required to invest in Novartis AG stocks?

To invest, you typically need:

What is the PE and PB ratio of Novartis AG?

The PE ratio of Novartis AG is 20.40 and the PB ratio is 6.04.